RecruitingNCT06151119

68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.

A Study to Evaluate 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.

Sponsor

The First Affiliated Hospital of Xiamen University

Enrollment

90 participants

Start Date

Nov 22, 2023

Study Type

OBSERVATIONAL

Conditions

Primary Myelofibrosis

Summary

To evaluate the diagnostic efficacy of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades. To evaluate the diagnostic efficacy of 68Ga FAPIPET/CT imaging in patients with myelofibrosis, compared with conventional CT.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Age ≥18 years old;
Cohort 1: Patients with suspected or confirmed myelofibrosis; Cohort 2: Patients with primary/secondary myelofibrosis who were not treated with ruxolitinib.
The expected survival time is over 3 months
Voluntarily sign informed consent.
Willing and able to follow the research protocol;
The subject must be able to lie on the scanning bed for 20 minutes;

Exclusion Criteria9

Known allergic history to 68Ga FAPI or its excipients;
Patients who can not tolerate intravenous drug administration (such as needle fainting and blood fainting history);
Those who are not suitable for or unable to complete imaging tests such as PET due to special reasons, including claustrophobia and radiophobia;
pregnant and lactating women;
Workers who are exposed to radiation for a long period of time;
Serious diseases of the heart, kidney, lung, blood vessel, nervous system, mental system, immune deficiency diseases and hepatitis/cirrhosis;
Participating in other interventional clinical trials within 1 month before screening;
Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy due to other cancers;
There are other circumstances that the researcher thinks are not suitable for participating in this study;